4.0
ImmunityBio, Inc. operates within the healthcare sector, in the biotechnology subsector focused on immunotherapies, and is listed on the Nasdaq under the ticker IBRX. The corporate structure originated from initiatives led by Patrick Soon-Shiong, centered on the development of biological platforms designed to stimulate the immune system in the treatment of cancer and infectious diseases.
Initial motivations involved the creation of technologies aimed at reducing the limitations of conventional therapies, expanding clinical options based on specific and durable immune responses. Early projects focused on the development of therapeutic vaccines, cell-based therapies, and immunomodulatory agents for oncology treatments.
The portfolio includes clinical-stage immunotherapy candidates, vector-based vaccine platforms, allogeneic cell therapies, NK and T-cell activation agents, as well as products targeting solid tumors and infectious diseases. Clinical programs span multiple phases of research, with an emphasis on bladder cancer, metastatic tumors, and therapeutic immunizations.
The market scope is international, with a predominant presence in the United States and participation in studies and scientific collaborations in other countries. Solutions are directed toward hospitals, cancer centers, clinical research networks, and bio-pharmaceutical partners engaged in therapeutic development.
Key market factors influencing performance include dynamics within the biopharmaceutical sector, competition in oncology immunotherapies, regulatory cycles, levels of investment in research and development, and clinical indicators tied to the approval of innovative therapies. Changes in healthcare policy and treatment access also impact operational outlooks.
Operational scale encompasses multiple clinical programs and laboratory units dedicated to translational research, along with industrial structures focused on pilot-scale biological manufacturing. Specialized teams work in scientific research, clinical development, regulatory affairs, and biopharmaceutical manufacturing.
The operational framework is based on research centers, bioprocessing laboratories, clinical development units, and corporate areas dedicated to strategic management and scientific partnerships. Headquarters are located in Southern California, United States, with technical and clinical facilities distributed regionally according to regulatory and logistical requirements.
The registered trading ticker is IBRX, listed exclusively on the Nasdaq.
History and foundation
Founded in 2014 in California, the company began operations focused on immunotherapy platforms for cancer treatment, establishing preclinical programs and initial trials to validate immune responses in oncology applications.
The early years were marked by challenges related to regulatory progress and the transition from laboratory research to clinical stages, as well as the formation of partnerships with research centers and the expansion of the therapeutic pipeline.
Expansion occurred through the development of new immunological platforms, broadening therapeutic indications, increasing production capacity, and internationalizing clinical studies. The evolution also included greater participation in treatments for solid tumors and infectious diseases.
Key historical milestones include the offer pública inicial (IPO) conducted in 2015 by NantKwest, followed by the merger between NantKwest and ImmunityBio in 2021, consolidating operations under the ImmunityBio name, along with the submission of immunologic therapies to regulatory agencies in subsequent years.
Between 2020 and 2024, the company recorded progress in clinical trials for bladder cancer, capital raises for manufacturing expansion, regulatory updates, strategic agreements, and developments that influenced market expectations regarding innovative immunotherapy advancements during the period.
Additional Information
The Company ImmunityBio Inc. (United States), is listed on Nasdaq with a market value of $ 2.03 Billions, having an equity of $ -523.41 Millions.
The Company is listedthe in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 82.56 Millions, which generated a loss in the amount of $ -348.62 Millions.
As for its main indicators, the Company has a P/E ratio of -5.81, a P/BV ratio of -3.87 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker IBRX.
